318 related articles for article (PubMed ID: 26778118)
1. Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?
Rashidi A; Walter RB
Expert Rev Hematol; 2016; 9(4):335-50. PubMed ID: 26778118
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific immunotherapies for acute myeloid leukemia.
Buckley SA; Walter RB
Hematology Am Soc Hematol Educ Program; 2015; 2015():584-95. PubMed ID: 26637776
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Based Treatment of Acute Myeloid Leukemia.
Garfin PM; Feldman EJ
Curr Hematol Malig Rep; 2016 Dec; 11(6):545-552. PubMed ID: 27734262
[TBL] [Abstract][Full Text] [Related]
4. Update on antigen-specific immunotherapy of acute myeloid leukemia.
Buckley SA; Walter RB
Curr Hematol Malig Rep; 2015 Jun; 10(2):65-75. PubMed ID: 25896530
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
[TBL] [Abstract][Full Text] [Related]
7. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
Mahalleh M; Shabani M; Rayzan E; Rezaei N
Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
[TBL] [Abstract][Full Text] [Related]
8. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Laszlo GS; Estey EH; Walter RB
Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
[TBL] [Abstract][Full Text] [Related]
9. The role of CD33 as therapeutic target in acute myeloid leukemia.
Walter RB
Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
[TBL] [Abstract][Full Text] [Related]
10. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
Walter RB
Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
[TBL] [Abstract][Full Text] [Related]
11. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
13. Gemtuzumab ozogamicin in acute myeloid leukemia.
Godwin CD; Gale RP; Walter RB
Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
[TBL] [Abstract][Full Text] [Related]
14. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
Godwin CD; Laszlo GS; Fiorenza S; Garling EE; Phi TD; Bates OM; Correnti CE; Hoffstrom BG; Lunn MC; Humbert O; Kiem HP; Turtle CJ; Walter RB
Leukemia; 2021 Sep; 35(9):2496-2507. PubMed ID: 33589747
[TBL] [Abstract][Full Text] [Related]
15. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
Linenberger ML
Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
[TBL] [Abstract][Full Text] [Related]
16. [Anti-CD33 monoclonal antibody drug conjugate--Gemtuzumab ozogamicin (GO)].
Usui N
Nihon Rinsho; 2015 Feb; 73 Suppl 2():215-8. PubMed ID: 25831755
[No Abstract] [Full Text] [Related]
17. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
18. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
19. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]